Navigation Links
PAREXEL Strengthens Late Phase and Observational Research Capabilities With Expert Team to Help Biopharma Meet Commercialization Goals
Date:11/23/2011

al results, future growth and customer demand.
For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should,"  "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated additional restructuring charges of approximately $4 million in the second quarter of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, politic
'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PAREXEL Advances Early Phase CNS Research Capabilities With Leading Medical Imaging Technology
2. UCB and PAREXEL Sign Strategic Partnership Agreement
3. PAREXEL International to Present at Lazard Capital Markets Healthcare Conference and Citi Small/Mid Cap Conference
4. PAREXEL Commercialization Experts to Present Best-Practice Approaches for Demonstrating Product Value at ISPOR Annual European Congress
5. PAREXEL Reports First Quarter Fiscal Year 2012 Financial Results
6. PAREXEL Expands Commercialization Capabilities With Dedicated Team to Help Biopharma Companies Demonstrate Product Value
7. New PAREXEL Podcast Series to Deliver Clinical Development and Commercialization Thought Leadership
8. PAREXEL and National University of Singapore Establish Program in Singapore to Meet Increasing Demand in Asia for Clinical Research Talent
9. PAREXEL Announces Date of First Quarter Fiscal Year 2012 Earnings Release and Conference Call
10. Experts to Provide Successful Strategies for Global Biopharmaceutical Development and Commercialization at PAREXEL Tokyo Seminar
11. PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... According to the new ... (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User (Research, ... Synthesis, NGS, DNA, RNAi) - Global Forecast to ... Market is expected to reach $1,712.1 Million by ... a CAGR of 9.8% from 2014 to 2019.. ...
(Date:8/29/2014)... , Aug. 29, 2014  In part ... to leverage a hospital pharmacy as a strategic asset, ... national practice leader for Cardinal Health,s Innovation Delivery Solutions ... care can benefit both hospitals and patients. ... only one part of their job in a value-based ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... Soft Tissue Repair Devices Market 2014-2018" report to ... the mass of cells that connect, support, or surround ... such as tendons, ligaments, cartilage, fascia, and other fibrous ... these tissues with age result in wear and tear ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3
... Minn., Oct. 14 AbbeyMoor Medical Inc. ... CPT code by the American Medical Association (AMA) for ... action, effective in January 2010, upgrades The Spanner from ... Category I procedure code for established procedures. This major ...
... 14 CardioGenics Holdings Inc. (OTC Bulletin Board: JAGH), provides ... in the company,s name, ticker symbol and CUSIP number. ... FINRA all documentation requested in connection with the name change, ... number for the company,s common shares. FINRA is working ...
Cached Medicine Technology:AbbeyMoor Medical Receives Category I CPT(R) Code for The Spanner(TM) Prostatic Stent Procedure 2AbbeyMoor Medical Receives Category I CPT(R) Code for The Spanner(TM) Prostatic Stent Procedure 3CardioGenics Holdings Inc. Provides Update on FINRA Submission Regarding Name Change 2
(Date:8/30/2014)... (PRWEB) August 30, 2014 "I had a ... of her crutches," said an inventor from Wetumpka, Ala. "In ... and sounds of the shore, I came up with a ... , She created a prototype for the patent-pending Deezers to ... enables the individual to use crutches, walkers, or canes at ...
(Date:8/30/2014)... 30, 2014 In today’s world, a ... difficult to get. Snoring and sleep apnea (a medical ... stops) robs people and their bed partners of the ... to 45% of the population snores and 20 million ... Of these, only 10% have been diagnosed and treated; ...
(Date:8/30/2014)... 30, 2014 The new review published by ... created by Karen Brimeyer, who wanted to make her guide ... This guide is now easy to find in the form ... this guide, the author of the new method shares all ... Daily Gossip writes in its review that the leaky gut ...
(Date:8/30/2014)... LiveStreamingFitness.com, a company dedicated to providing live ... resources, is proud to announce it has been recognized as ... fitness solutions by ABC’s Good Morning America. ... Good Morning America, “Live Streaming Fitness is the hottest new ... by streamlining your workout…to boot camp at Life Streaming Fitness ...
(Date:8/30/2014)... August 30, 2014 When a prominent bank ... as happened on Wednesday, August 27th, when news began surfacing ... JPMorgan Chase & Co and at least one other ... actually investigating attacks on seven prominent banks , everyone ... be affected, and the buzz quickly goes viral. Bloomberg ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Leaky Gut Cure Review Reveals Unique Method to Stop Chronic Symptoms 2Health News:LiveStreamingFitness.com is New Trend In Fitness 2Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 2Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 3Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 4Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 5
... at Harvard University have created a laboratory model using ... stages of ovarian cancer metastasis. "We were ... for the force-dependent processes associated with metastasis," said Joan ... Harvard University. These findings are published in ...
... awarded Penn State, Penn State Milton S. Hershey Medical ... million, five-year grant designed to accelerate the translation of ... This competitive Clinical and Translational Science Award (CTSA) will ... (CTSI), a collaboration of many Penn State colleges and ...
... , TUESDAY, June 14 (HealthDay News) --,Scheduling classes later in ... in the morning, but it may also encourage them to ... that undergrads whose classes started later were more likely to ... times predicted more drinking, more sleep time and modestly lower ...
... liver fibrosis, such as liver stiffness measurement or the ... C, according to a new study in Gastroenterology ... (AGA) Institute. "Liver stiffness measurement and/or the ... hepatitis C, regardless of the stage of the disease," ...
... 15, the Lymphoma Research Foundation (LRF), in collaboration with ... Center, will bring together lymphoma experts to discuss the ... This event is the final installation of LRF,s 2010-2011 ... series focused on the diagnosis and treatment of lymphoma ...
... Tiny fibres used to strengthen everyday products such as bicycle ... involved in their manufacture. Certain types of carbon nanotubes ... human hair could cause cancer in the lining of ... study in mice found that while short carbon nanotubes appeared ...
Cached Medicine News:Health News:Penn State receives $27.3 million NIH grant 2Health News:Penn State receives $27.3 million NIH grant 3Health News:Penn State receives $27.3 million NIH grant 4Health News:College Students Who Sleep in Drink More, Study Less 2Health News:Noninvasive liver tests may predict hepatitis C patient survival 2Health News:Lymphoma Research Foundation and John Theurer Cancer Center collaborate for Lymphoma Rounds program 2
... while minimizing the pain of ... safety-engineered BD Microtainer Genie Lancet. ... offers a full range of ... blood collection and protects the ...
The DiaSTAT™ is an automated liquid chromatography system designed for the rapid and automated analysis of hemoglobin A1C. Ideal for low and ,medium volume testing environments....
The HEMOCHRON Jr. Signature+ Microcoagulation System offers point-of-care monitoring with numerous features to meet the needs of each individual department, as well as the needs of regulatory complia...
Inquire...
Medicine Products: